Werner Klingenberg, Goldplat CEO outlines his growth strategy at the London South East May webinar. Watch the full video here.
|Evgen Pharma Share Price|
|Shares in Issue||275m|
|52 Week High||9.30|
|52 Week High Date||10-Jun-2021|
|52 Week Low||3.075|
|52 Week Low Date||24-Mar-2022|
|31-Mar-21||31-Mar-21||Notification of Holding||Susan (Sue) Foden held the position of Non-Executive Director at the time of this trade. Susan (Sue) Foden||0.00||0||125,000|
|31-Mar-21||31-Mar-21||Notification of Holding||Huw Jones held the position of CEO at the time of this trade. Huw Jones||0.00||0||62,500|
|31-Mar-21||31-Mar-21||Notification of Holding||Barry Clare held the position of Non-Executive Chairman at the time of this trade. Barry Clare||0.00||0||1,023,441|
|05-Mar-21||03-Mar-21||Placing||Richard Moulson held the position of CFO at the time of this trade. Richard Moulson||8.00||GBX||3,787||45,454|
|19-Jan-16||18-Jan-16||Buy||John Bradshaw held the position of CFO at the time of this trade. John Bradshaw||22.25||GBX||40,000||40,000|
Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions and the lead product is SFX-01.